Inventiva S.A. (IVA)
After hours:
| Previous Close | 1.6900 |
| Open | 1.6800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.6300 - 1.6900 |
| 52 Week Range | 1.5300 - 4.7500 |
| Volume | |
| Avg. Volume | 9,692 |
| Market Cap | 87.082M |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of key
- GlobeNewswire
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term deposits as of December 31, 2023.On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng) for an amount of approximately €20.1 million.No Revenues recorded in H1 2024, compared to €1.9 million for the same perio
- GlobeNewswire
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrhosis due to MASH/NASH. Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on t
